ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells $555,000.00 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 50,000 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $11.10, for a total value of $555,000.00. Following the sale, the director now directly owns 210,346 shares in the company, valued at $2,334,840.60. This represents a 19.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Laura Shawver also recently made the following trade(s):

• On Monday, December 2nd, Laura Shawver sold 97,244 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $13.56, for a total value of $1,318,628.64.
• On Wednesday, December 4th, Laura Shawver sold 14,772 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $13.75, for a total value of $203,115.00.

ARS Pharmaceuticals Stock Up 0.8 %

Shares of ARS Pharmaceuticals stock opened at $11.43 on Friday. ARS Pharmaceuticals, Inc. has a 52 week low of $5.68 and a 52 week high of $18.51. The firm’s 50 day moving average is $13.11 and its two-hundred day moving average is $12.67. The firm has a market capitalization of $1.11 billion, a P/E ratio of -22.41 and a beta of 0.96.

Analysts Set New Price Targets

Several brokerages recently weighed in on SPRY. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $30.00 target price on shares of ARS Pharmaceuticals in a report on Tuesday, October 8th. Leerink Partners lifted their price objective on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a research report on Friday, September 20th. Four investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, ARS Pharmaceuticals has an average rating of “Buy” and a consensus target price of $24.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. nVerses Capital LLC acquired a new position in ARS Pharmaceuticals in the third quarter valued at $30,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ARS Pharmaceuticals by 151.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after purchasing an additional 4,472 shares during the period. Principal Financial Group Inc. purchased a new position in ARS Pharmaceuticals during the 2nd quarter worth approximately $87,000. J.W. Cole Advisors Inc. increased its position in ARS Pharmaceuticals by 10.8% during the second quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock worth $131,000 after buying an additional 1,500 shares during the period. Finally, Quarry LP purchased a new stake in ARS Pharmaceuticals in the third quarter valued at approximately $174,000. 68.16% of the stock is owned by hedge funds and other institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.